DAX ®12.670,11+0,32%TecDAX ®2.801,74-0,15%Dow Jones27.001,98-0,08%NASDAQ 1007.920,21-0,29%
finanztreff.de

BUSINESS WIRE: Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite

| Quelle: Business_Wire | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

FOSTER CITY, Calif. (BUSINESS WIRE) 11.07.2019

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Christi L. Shaw will join the company as Chief Executive Officer of Kite, a Gilead Company, and will become a member of Gilead’s senior leadership team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190711005777/en/

Ms. Shaw is a renowned leader with deep experience providing commercial, financial, strategic, medical and operations leadership across the biopharmaceutical industry. Ms. Shaw currently serves as Senior Vice President of Eli Lilly &. Co., and President of Lilly Bio-Medicines. She also serves as a board member of both Avantor, Inc. and the Biotechnology Industry Organization (BIO), and as an advisor to the Healthcare Businesswomen’s Association.

Prior to joining Lilly, Ms. Shaw most recently served as U.S. Country Head and President of Novartis Corp. and North American Head of Novartis Oncology. She earned a BA in Business Administration from Iowa State University and an MBA from the University of Wisconsin.

“We conducted an extensive search for a new leader at Kite and we believe that Christi’s unique set of skills will allow us to continue to build on our leadership position in cell therapy,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “Christi’s vast experience across complex therapeutic areas, and particularly in oncology, will serve Kite very well. She is clearly a leader who will bring teams and individuals together and I am confident she will build upon the entrepreneurial spirit at Kite as we seek to help more people with cancer around the world.”

“Kite’s vision of transformational drug development – and of curing cancer – is one that I am extremely passionate about,” said Ms. Shaw. “I look forward to working with the many talented individuals in this organization, as we change the way cancer is treated and bring forward important, life-saving therapies.”

About Kite

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

For more information on Kite, please visit the company’s website at www.kitepharma.com. Learn more about Gilead at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Sung Lee, Investors
(650) 524-7792

Shant Salakian, Media
(424) 384-1841

Werbung

Das könnte Sie auch interessieren

Weitere Nachrichten

Quelle: Business_Wire
16.10. BUSINESS WIRE: Murray Energy Corporation estende gli accordi di dilazione con i suoi creditori e decide di non versare gli interessi agli obbligazionisti
16.10. BUSINESS WIRE: Bank of America veröffentlicht Finanzergebnisse für das dritte Quartal 2019
16.10. BUSINESS WIRE: Die Leistungen von Dr. Steven Rosenberg bei der Krebsimmuntherapie inspirieren junge Forscher in Japan; Sieg beim XIV. Fujio Cup-Quiz zu Stammzellen geht an Indien.
16.10. BUSINESS WIRE: Mavenir bringt vollständig virtualisierte 4G/5G OpenRAN-Lösung auf den Markt
16.10. BUSINESS WIRE: ExaGrid annuncia una nuova soluzione di archiviazione dati per il backup informatico di Acronis
16.10. BUSINESS WIRE: Mavenir lancia la soluzione per reti 4G/5G OpenRAN completamente virtualizzata
16.10. BUSINESS WIRE: ExaGrid kündigt neue Datenspeicherlösung für Acronis Cyber Backup an
16.10. BUSINESS WIRE: Odaseva viene nominata leader globale nel cloud computing
16.10. BUSINESS WIRE: Taulia lancia un avanzato strumento per la previsione dell'andamento dei flussi di cassa ad EuroFinance Copenhagen 2019
16.10. BUSINESS WIRE: Tealium Expands Leadership Team, Appoints World-Class Marketing Executive as CMO
Rubrik: Finanzmarkt
16.10. ROUNDUP 3: Paris und Berlin schließen Abkommen für Rüstungsexporte
16.10. Dritte Nacht mit schweren Krawallen in Barcelona - Autos angezündet
16.10. ANALYSE-FLASH: RBC senkt Ziel für Continental AG auf 120 Euro - 'Sector Perform' CONTINENTAL 118,58 +0,58%
16.10. ANALYSE-FLASH: RBC hebt Ziel für Volkswagen Vorzüge (VW) - 'Outperform' VOLKSWAGEN VZ 168,52 +2,46%
16.10. ANALYSE-FLASH: RBC hebt Ziel für BMW auf 74 Euro - 'Sector Perform' BMW ST 67,24 +1,20%
16.10. Netflix gewinnt dank 'Stranger Things' wieder kräftig Kunden hinzu APPLE 211,05 -1,38%
16.10. 1000-Pfund-Bombe in Hamburg entschärft: Flüge starten wieder LUFTHANSA 15,33 +1,89%
16.10. ROUNDUP/Aktien New York Schluss: Leichte Verluste - Daten und Handelssorgen Dow Jones 27.001,98 -0,08%
16.10. IBM enttäuscht mit Gewinneinbruch und Umsatzrückgang IBM 124,65 -4,00%
16.10. Aktien New York Schluss: Leichte Verluste - Schwache Daten und Handelssorgen Dow Jones 27.001,98 -0,08%

News-Suche

Suchbegriff:

Aktuelle Videos

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Immer mehr Unterstützer für Facebooks Kryptowährung Libra steigen aus. Glauben Sie, dass dieses Facebook-Projekt scheitern könnte?
Jetzt abstimmen!
Alle Umfragen ansehen